Foresight Diagnostics announced a strategic, worldwide partnership with Qiagen (QGEN) to develop and commercialize a kit-based version of Foresight’s CLARITY assay, with the goal of enabling global in vitro diagnostic and companion diagnostic applications in lymphoma and other hematological malignancies. “This collaboration combines Foresight’s innovative MRD detection technology with Qiagen’s global leadership in molecular diagnostic development and commercialization. Together, the companies aim to lay the groundwork for a standardized, regulated diagnostic kit that, once validated and approved in pharmaceutical-sponsored trials, would be the only circulating tumor DNA-based MRD assay available as both a central laboratory service and diagnostic kit capable of supporting clinical decision-making and therapeutic strategies for patients with hematological cancers,” the companies stated.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QGEN:
- Qiagen expands digital PCR oncology research portfolio
- Citi opens ‘upside 90-day short-term view’ on Qiagen
- Cautious Optimism for Qiagen Amidst Industry Challenges: Awaiting Long-term Growth Assurance
- Qiagen’s Strong Positioning and Growth Potential Earns Buy Rating from Analyst
- Qiagen Receives Notification of BlackRock’s Voting Rights